Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Publisher: La Merie Publishing
Pages: 89
Format: PDF
Product Line:
Target Pipeline
Product Line:
Competitor Analysis
Product Code: LMCA0156
Release Date: June of 2018

600.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

This Competitive Intelligence report analyzes the competitive field of PD-1 and PD-L1 Immune Checkpoint Inhibitors as of June 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage separately for regulated and less regulated markets and differentiates between specific and bi- or multispecific molecules.

Five antibody products targeting the programmed death receptor 1 (PD-1) or the programmed death-ligand 1 (PD-L1) have been approved. Combined sales of the four checkpoint inhibitors marketed in the year 2017 exceeded US$ 10 bln with double and triple digit growth rates, respectively, compared with sales of the previous year. The enormous clinical and commercial success is attracting many biopharmaceutical companies, not only from countries with regulated pharmaceutical markets (USA; Europe, Japan), but also from countries with less regulated markets, especially China.

Analysis of the PD-1 and PD-L1 checkpoint inhibitor pipeline revealed 41 unique molecules in clinical development by pharmaceutical companies, of which 12% are bispecific molecules and 27% are only developed so far in less regulated countries. Further 15 unique molecules are undergoing IND-enabling studies or have already applied for clinical trial of which 40% are bispecific molecules. Most of the molecules are recombinant antibodies or antibody fusion proteins, but some other treatment modalities, such as small molecules, are also appearing in the pipeline.

The report includes a compilation of currently active projects in research and development of mostly recombinant antibodies, but also fusion proteins, small molecules and RNAi targeting programmed death receptor 1 (PD-1) or the programmed death-ligand 1 (PD-L1). In addition, the report lists company-specific R&D pipelines of PD-1 and PD-L1 checkpoint inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Table of Contents:

1)        PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

1a) PD-1 Receptor Antagonists:

  • Approved and Marketed PD-1 Antagonists 
  • Specific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
  • Specific PD-1 Antagonists in Non- or Pre-Clinical Development
  • Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development

1b) PD-L1 Inhibitors:

  • Approved and Marketed PD-L1 Inhibitors 
  • Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
  • Specific PD-L1 Inhibitors in Non- and Preclinical Development
  • Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development

2)        Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top